[
  {
    "drug_name": "semaglutide",
    "condition": "obesity",
    "global_market_size_usd_bn": 25.4,
    "forecast_market_size_usd_bn_2030": 68.0,
    "cagr_percent": 18.5,
    "patient_population_millions": 650,
    "treated_population_percent": 6.2,
    "number_of_competitors": 8,
    "branded_vs_generic_mix": "branded-dominant",
    "key_competitor_classes": ["GLP-1 agonists", "Dual GLP-1/GIP"],
    "commercial_signals": [
      "Strong payer uptake in US and EU",
      "Supply constraints impacting near-term sales"
    ],
    "risks": [
      "Pricing pressure from next-generation incretins",
      "Long-term cardiovascular outcomes scrutiny"
    ]
  },
  {
    "drug_name": "semaglutide",
    "condition": "type 2 diabetes",
    "global_market_size_usd_bn": 45.0,
    "forecast_market_size_usd_bn_2030": 72.5,
    "cagr_percent": 9.8,
    "patient_population_millions": 420,
    "treated_population_percent": 28.0,
    "number_of_competitors": 12,
    "branded_vs_generic_mix": "branded-heavy",
    "key_competitor_classes": ["GLP-1 agonists", "Insulin", "SGLT2 inhibitors"],
    "commercial_signals": [
      "GLP-1s shifting standard of care",
      "Strong guideline support"
    ],
    "risks": [
      "Formulary exclusions in price-sensitive markets"
    ]
  },
  {
    "drug_name": "metformin",
    "condition": "nonalcoholic steatohepatitis",
    "global_market_size_usd_bn": 6.2,
    "forecast_market_size_usd_bn_2030": 21.0,
    "cagr_percent": 22.1,
    "patient_population_millions": 115,
    "treated_population_percent": 2.5,
    "number_of_competitors": 15,
    "branded_vs_generic_mix": "generic-heavy",
    "key_competitor_classes": ["Metabolic modulators", "FXR agonists"],
    "commercial_signals": [
      "High unmet need with no approved therapies",
      "Multiple late-stage pipeline assets"
    ],
    "risks": [
      "High clinical failure rates in NASH",
      "Regulatory uncertainty on endpoints"
    ]
  },
  {
    "drug_name": "naltrexone",
    "condition": "crohnâ€™s disease",
    "global_market_size_usd_bn": 14.8,
    "forecast_market_size_usd_bn_2030": 26.0,
    "cagr_percent": 7.3,
    "patient_population_millions": 6.5,
    "treated_population_percent": 65.0,
    "number_of_competitors": 10,
    "branded_vs_generic_mix": "biologic-dominant",
    "key_competitor_classes": ["Anti-TNF", "IL-23 inhibitors"],
    "commercial_signals": [
      "Biologics dominate prescribing",
      "Interest in low-cost oral adjuncts"
    ],
    "risks": [
      "Crowded biologics market",
      "Switching barriers"
    ]
  },
  {
    "drug_name": "minoxidil",
    "condition": "alopecia",
    "global_market_size_usd_bn": 9.5,
    "forecast_market_size_usd_bn_2030": 15.2,
    "cagr_percent": 6.1,
    "patient_population_millions": 180,
    "treated_population_percent": 12.0,
    "number_of_competitors": 6,
    "branded_vs_generic_mix": "generic-dominant",
    "key_competitor_classes": ["Topical vasodilators", "Anti-androgens"],
    "commercial_signals": [
      "Strong OTC demand",
      "Cosmetic dermatology driven growth"
    ],
    "risks": [
      "Low barriers to entry",
      "Limited pricing power"
    ]
  },
  {
    "drug_name": "ketamine",
    "condition": "treatment-resistant depression",
    "global_market_size_usd_bn": 3.8,
    "forecast_market_size_usd_bn_2030": 9.4,
    "cagr_percent": 16.7,
    "patient_population_millions": 30,
    "treated_population_percent": 4.0,
    "number_of_competitors": 5,
    "branded_vs_generic_mix": "branded-specialty",
    "key_competitor_classes": ["NMDA antagonists", "Psychedelic-assisted therapy"],
    "commercial_signals": [
      "Clinic-based administration models",
      "Rapid onset differentiates from SSRIs"
    ],
    "risks": [
      "Abuse potential",
      "Reimbursement uncertainty"
    ]
  },
  {
    "drug_name": "n-acetylcysteine",
    "condition": "copd",
    "global_market_size_usd_bn": 18.2,
    "forecast_market_size_usd_bn_2030": 24.1,
    "cagr_percent": 4.8,
    "patient_population_millions": 300,
    "treated_population_percent": 35.0,
    "number_of_competitors": 20,
    "branded_vs_generic_mix": "generic-heavy",
    "key_competitor_classes": ["Bronchodilators", "Mucolytics"],
    "commercial_signals": [
      "Broad global usage",
      "Strong presence in emerging markets"
    ],
    "risks": [
      "Low differentiation",
      "Price erosion"
    ]
  },
  {
    "drug_name": "spironolactone",
    "condition": "adult female acne",
    "global_market_size_usd_bn": 7.1,
    "forecast_market_size_usd_bn_2030": 11.3,
    "cagr_percent": 6.9,
    "patient_population_millions": 90,
    "treated_population_percent": 18.0,
    "number_of_competitors": 9,
    "branded_vs_generic_mix": "generic-dominant",
    "key_competitor_classes": ["Hormonal therapies", "Retinoids"],
    "commercial_signals": [
      "Off-label prescribing growth",
      "High dermatologist acceptance"
    ],
    "risks": [
      "Lack of formal indication",
      "Monitoring requirements"
    ]
  },
  {
    "drug_name": "propranolol",
    "condition": "performance anxiety",
    "global_market_size_usd_bn": 2.6,
    "forecast_market_size_usd_bn_2030": 4.1,
    "cagr_percent": 5.8,
    "patient_population_millions": 55,
    "treated_population_percent": 9.0,
    "number_of_competitors": 7,
    "branded_vs_generic_mix": "generic-heavy",
    "key_competitor_classes": ["Beta blockers", "Anxiolytics"],
    "commercial_signals": [
      "Event-driven usage pattern",
      "Strong physician familiarity"
    ],
    "risks": [
      "Off-label reimbursement limits"
    ]
  },
  {
    "drug_name": "amantadine",
    "condition": "post-covid fatigue",
    "global_market_size_usd_bn": 4.9,
    "forecast_market_size_usd_bn_2030": 12.8,
    "cagr_percent": 20.4,
    "patient_population_millions": 80,
    "treated_population_percent": 3.5,
    "number_of_competitors": 4,
    "branded_vs_generic_mix": "generic-light",
    "key_competitor_classes": ["CNS stimulants", "Neuro-modulators"],
    "commercial_signals": [
      "Emerging long-COVID clinics",
      "Limited therapeutic options"
    ],
    "risks": [
      "Unclear regulatory pathways",
      "Heterogeneous patient definitions"
    ]
  },
  {
  "drug_name": "ketamine",
  "condition": "postpartum depression",
  "global_market_size_usd_bn": 1.2,
  "forecast_market_size_usd_bn_2030": 3.6,
  "cagr_percent": 14.8,
  "patient_population_millions": 12,
  "treated_population_percent": 6,
  "number_of_competitors": 3,
  "branded_vs_generic_mix": "branded-dominant",
  "key_competitor_classes": [
    "NMDA antagonists",
    "neurosteroid antidepressants"
  ],
  "commercial_signals": [
    "Growing recognition of postpartum depression as a distinct treatable condition",
    "Rapid-acting antidepressants gaining payer interest",
    "Specialty clinic-driven adoption"
  ],
  "risks": [
    "Administration setting constraints (IV/clinic-based)",
    "Safety and abuse perception risks",
    "Reimbursement variability across regions"
  ]
}
]
